CD274 and neoplasm: Barriers in the implementation and evaluation of companion diagnostic biomarker tests that are used to stratify patients for ICIs (i.e. tumor cell expression of PD‐L1 and tumor mutation burden assessment) suggest that much remains to be discovered to fully understand ICI response.